Myriad Genetics Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the third quarter 2026 to a ratio of 7.08, above the company average. This is a clear sign of healthy business climate in the In Vitro & In Vivo Diagnostic Substances industry and improving liquidity at their respective customers, during the third quarter 2026. Average receivable collection period, for the Myriad Genetics Inc in Sep 30 2026 quarter, has decreased to 52 days, compared to 53 days, in the Jun 30 2026 quarter.

If we take a look into Healthcare sector 65 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Sep 30 2026 from 202 to 663.

What is Receivable Turnover Ratio?
What is Myriad Genetics Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

MYGN Receivables Turnover Ratio	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Receivable Change	-10.59 %	-20.07 %	2.82 %	-4.87 %	-6.13 %
Y / Y Revenue Change	-1.03 %	-10.39 %	2.25 %	0.19 %	-3.98 %
Receivable Turnover Ratio (TTM)	7.08	6.91	6.7	6.71	6.63
MYGN's Total Ranking	# 663	# 202	# 511	# 1885	#
Accounts Receivable average collection period days	52	53	54	54	55
Seq. Receivable Change	-3.65 %	-11.55 %	7.37 %	-2.29 %	-13.87 %
Seq. Revenue Change	6.29 %	-4.46 %	-5.31 %	2.93 %	-3.76 %

Receivable Turnover Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 3
Healthcare Sector	# 66
Overall Market	# 663

Receivable Turnover Ratio Statistics
High	Average	Low
1.19	0.71	0.41
(Mar 31 2026)		(Sep 30 2020)

News about Myriad Genetics Inc Receivables Turnover Ratios

In a significant stride towards enhancing access and equity in genetic testing, Myriad Genetics, Inc. (NASD...

Advancing Genetic Testing: Myriad Genetics’ Strategic Partnerships to Transform Precision Medicine In a significant stride towards enhancing access and equity in genetic testing, Myriad Genetics, Inc. (NASDAQ: MYGN), renowned for its leadership in genetic testing and precision medicine, has embarked on multiple collaborative initiatives designed to steer the future of personalized medicine and expand the horizons of genomic research. Through strategic partnerships with JScreen, Ultima Genomics, and QIAGEN, Myriad Genetics is set to revolutionize genetic testing capabilities and offer more inclusive health solutions. Enhancing Health Equity with JScreen Recognizing the pressing need for equitable healthcare access, Myriad Genetics has partnered with JScreen, an esteemed organization dedicated to genetic screening and education. This collaboration is a pivotal step towards democratizing genetic testing and ensuring that diverse populations receive the benefits of early genetic disease detection and personalized care strategies. The alliance underscores a shared commitment to health equity, empowering individuals with the information needed to make informed healthcare decisions regardless of their socio-economic background.

MYGN Company Profile • Back to MYGN Efficiency Comparisons • Compare MYGN Receivables Turnover Ratio to its Competitors

Financial Statements
Myriad Genetics Inc 's Accounts Receivable	$ 106 Millions	Visit MYGN's Balance sheet
Myriad Genetics Inc 's Sales TTM	$ 804 Millions	Visit MYGN's Income Statement
Sources of MYGN's Revenues		Visit MYGN's Sales by Geography

Other Accounts Receivable Turnover Ratios
In Vitro & In Vivo Diagnostic Substances Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
MYGN's Receivable Turnover Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
MYGN's Growth Rates	MYGN's Roa	MYGN's Inventory Turnover Ratio	MYGN's Dividend Comparisons
MYGN's Profitability Ratios	MYGN's Roi	MYGN's Asset Turnover Ratio	MYGN's Dividend Growth
MYGN's Valuation Ratios	MYGN's Roe	MYGN's Financial Strength Ratios	MYGN's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Sep 30 2026	Receivable at quarter ending Sep 30 2026
Arvinas Inc	20.06	$ 275.300 Millions	$ 13.725 Millions
U S Physical Therapy Inc	18.16	$ 837.629 Millions	$ 46.137 Millions
Alpha Pro Tech Ltd	17.54	$ 64.940 Millions	$ 3.702 Millions
Biogen Inc	15.19	$ 10,297.300 Millions	$ 677.900 Millions
Lifestance Health Group Inc	14.89	$ 1,676.889 Millions	$ 112.631 Millions
Amneal Pharmaceuticals Inc	14.24	$ 3,196.184 Millions	$ 224.488 Millions
Corcept Therapeutics Inc	13.44	$ 963.647 Millions	$ 71.710 Millions
Precipio inc	13.38	$ 27.762 Millions	$ 2.075 Millions
Chemed Corporation	12.65	$ 2,661.041 Millions	$ 210.387 Millions
Caredx Inc	11.75	$ 497.396 Millions	$ 42.330 Millions
Teladoc Health Inc	11.50	$ 2,468.143 Millions	$ 214.604 Millions
Biodesix Inc	11.45	$ 105.212 Millions	$ 9.192 Millions
Gossamer Bio Inc	11.37	$ 78.423 Millions	$ 6.896 Millions
Icu Medical Inc	11.32	$ 2,183.556 Millions	$ 192.845 Millions
Mannkind Corporation	10.97	$ 413.370 Millions	$ 37.686 Millions
Lensar Inc	10.64	$ 60.079 Millions	$ 5.645 Millions
Iqvia Holdings Inc	10.43	$ 17,311.000 Millions	$ 1,659.500 Millions
Voyager Therapeutics Inc	9.84	$ 25.108 Millions	$ 2.551 Millions
Myomo Inc	9.66	$ 47.775 Millions	$ 4.947 Millions
Encompass Health Corporation	9.41	$ 6,338.100 Millions	$ 673.625 Millions
Bausch Health Companies Inc	9.15	$ 11,113.000 Millions	$ 1,215.000 Millions
Co diagnostics Inc	9.12	$ 0.859 Millions	$ 0.094 Millions
Pacs Group Inc	8.88	$ 5,705.049 Millions	$ 642.729 Millions
Lexicon Pharmaceuticals Inc	8.77	$ 38.537 Millions	$ 4.396 Millions
Axogen inc	8.71	$ 266.926 Millions	$ 30.654 Millions
Avita Medical Inc	8.65	$ 84.683 Millions	$ 9.795 Millions
Ensign Group Inc	8.62	$ 5,674.305 Millions	$ 658.477 Millions
Pediatrix Medical Group Inc	8.57	$ 1,959.124 Millions	$ 228.471 Millions
Tenet Healthcare Corp	8.54	$ 22,154.000 Millions	$ 2,593.250 Millions
Brightspring Health Services Inc	8.50	$ 9,479.144 Millions	$ 1,114.763 Millions

Date modified: 2026-11-07T13:15:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.